健康供者和慢性淋巴细胞白血病患者 B 细胞上 CD1d 和 ULBP3 的上调并不能使其易于被γδ T 细胞杀伤
Upregulation of CD1d and ULBP3 on B cells from healthy donors and chronic lymphocytic leukaemia patients does not prime them for killing by γδ T cells
肿瘤细胞治疗研究
MODALITY HUB
FOR TREATMENT
现在就能报名的(招募中)排在最前,共 2 项。同一状态内中国中心优先。信息来自 ClinicalTrials.gov、CDE 与 ChiCTR 公开登记。能否入组、费用与可及性,以登记原文和主治医生判断为准。
FOR RESEARCH
Upregulation of CD1d and ULBP3 on B cells from healthy donors and chronic lymphocytic leukaemia patients does not prime them for killing by γδ T cells
CCR5-targeted allogeneic gamma-delta CD19 chimeric antigen receptor T cells for HIV-associated B cell-malignancy immunotherapy.
CAR γδ T cells for cancer immunotherapy. Is the field more yellow than green?
Tafasitamab mediates killing of B-cell non-Hodgkin's lymphoma in combination with γδ T cell or allogeneic NK cell therapy.
Characteristics of Human Peripheral Blood γδ T Cells Expanded With Zoledronate.
γδ T 细胞可能是一种有前景的癌症免疫治疗手段。
MEMBER ACCOUNT
登录成功会直接打开下一页。